Lucid Diagnostics (LUCD) announced its intention to offer shares of common stock through an underwritten public offering. Canaccord Genuity and BTIG are acting as joint bookrunners of the offering and Maxim Group is acting as co-manager of the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Positive Outlook for Lucid Diagnostics: Medicare Coverage and Clinical Support Boost EsoGuard’s Market Potential
- Lucid Diagnostics price target raised to $2.50 from $2 at BTIG
- Positive Outlook on Lucid Diagnostics’ EsoGuard Test Driven by Clinician Support and Potential Medicare Coverage
- Positive Outlook on Lucid Diagnostics Driven by EsoGuard’s Clinical Efficacy and Potential Medicare Coverage
- Lucid Diagnostics Earnings Call: Optimism Amid Challenges